Trial: 201712132

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as
Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for
Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
(LA HNSCC)

Phase

III

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov